|This Slide: #32 of 100|
Slide #32. OPKO Health, Inc. — Inspiro Medical Ltd.
OPKO Health, Inc. (NASDAQ:OPK)
Inspiro Medical Ltd.
OPKO Health, Inc. (NYSE:OPK) has entered into a definitive agreement to acquire Inspiro Medical Ltd. ("Inspiro"), an Israeli medical device company developing a new platform to deliver small molecule drugs such as corticosteroids and beta agonists or larger molecules to treat respiratory diseases. Inspiro's Inspiromatic is a "smart" easy-to-use dry powder inhaler with several advantages over existing devices.
Opko Health is a healthcare company. Co.'s segments are diagnostics and pharmaceutical. Co.'s diagnostics segment provides laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional healthcare. Co.'s pharmaceutical business features Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator; and OPK88003, a once weekly oxyntomodulin for type 2 diabetes and obesity.
OPK SEC Filing Email Alerts Service
Open the OPK Page at The Online Investor »
Strong Buy (4.00 out of 4)
(ranked higher than approx. 87% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite